MedTrace Logo

Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

NCT00479492 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2009-10-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.

Conditions

Interventions

DRUG

CP-866,087

1 mg of CP-866,087, administered QD for 84 days

DRUG

CP-866,087

5 mg of CP-866,087, administered QD for 84 days

DRUG

CP-866,087

10 mg of CP-866,087, administered QD for 84 days

DRUG

placebo

placebo administered QD for 84 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479492 on ClinicalTrials.gov